London UK, 1st June 2015: Vasgen Limited (“Vasgen” or “the Company”), a London-based biotech company, reports that it will be attending the BIO International Convention in Philadelphia between 15th-18th June 2015 as part of a Mayor of London’s delegation of UK companies.
Dr Salman Rahman, CEO and co-founder of Vasgen said: “We are very grateful to the Mayor of London’s office for selecting our company to join this prestigious delegation of UK companies attending the BIO International 2015 convention. This offers a great opportunity for Vasgen to profile itself to a global biotech/pharma community represented at this convention. We look forward to meeting with many international companies and colleagues which share our interest in developing innovative antibody-based therapeutics for ophthalmology and oncology medicine.”
-Ends-
Notes to Editors:
Vasgen Ltd
Vasgen Limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs.
The Company’s technologies include AbIMP®, a novel antibody-based approach allowing development of highly selective inhibitors of metzincin metalloproteinases with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149